358 related articles for article (PubMed ID: 28168884)
1. Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients.
Chung EK; Fleming MR; Cheatham SC; Kays MB
Ann Pharmacother; 2017 Mar; 51(3):209-218. PubMed ID: 28168884
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
Kays MB; Fleming MR; Cheatham SC; Chung EK; Juenke JM
Ann Pharmacother; 2014 Feb; 48(2):178-86. PubMed ID: 24259653
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.
Bhalodi AA; Keel RA; Quintiliani R; Lodise TP; Nicolau DP; Kuti JL
Ann Pharmacother; 2013 May; 47(5):617-27. PubMed ID: 23585647
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.
Chung EK; Cheatham SC; Fleming MR; Healy DP; Shea KM; Kays MB
J Clin Pharmacol; 2015 Aug; 55(8):899-908. PubMed ID: 25823963
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections.
Lee DH; Kim YK; Jin K; Kang MJ; Joo YD; Kim YW; Moon YS; Shin JG; Kiem S
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223378
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients with Sepsis.
Rahbar AJ; Lodise TP; Abraham P; Lockwood A; Pai MP; Patka J; Rabinovich M; Curzio K; Chester K; Williams B; Morse B; Chaar M; Huang V; Salomone J
Surg Infect (Larchmt); 2016 Dec; 17(6):675-682. PubMed ID: 27841954
[TBL] [Abstract][Full Text] [Related]
8. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit.
Cheatham SC; Fleming MR; Healy DP; Chung EK; Shea KM; Humphrey ML; Kays MB
J Clin Pharmacol; 2014 Mar; 54(3):324-30. PubMed ID: 24122855
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.
Samtani MN; Flamm R; Kaniga K; Nandy P
Antimicrob Agents Chemother; 2010 Jun; 54(6):2360-4. PubMed ID: 20385857
[TBL] [Abstract][Full Text] [Related]
10. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
Lewis SJ; Kays MB; Mueller BA
J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
[TBL] [Abstract][Full Text] [Related]
11. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and monte carlo simulations of doripenem in patients with febrile neutropenia.
Stein GE; Kulhanek G; Smith CL; Kuti JL; Nicolau DP; Scharmen A; Farnum C; Tran M; Kalra A; Havlichek DH
Ann Pharmacother; 2012 Oct; 46(10):1281-6. PubMed ID: 23012385
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/Pharmacodynamic Analysis for Doripenem Regimens in Intensive Care Unit Patient.
Tanaka R; Sato Y; Goto K; Yasuda N; Ohchi Y; Suzuki Y; Ueno T; Ito K; Kaneko T; Kurogi S; Nonoshita K; Itoh H
Biol Pharm Bull; 2017; 40(8):1226-1231. PubMed ID: 28769004
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.
Abdul-Aziz MH; Abd Rahman AN; Mat-Nor MB; Sulaiman H; Wallis SC; Lipman J; Roberts JA; Staatz CE
Antimicrob Agents Chemother; 2016 Jan; 60(1):206-14. PubMed ID: 26482304
[TBL] [Abstract][Full Text] [Related]
15. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
Roberts JA; Lipman J
Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics and pharmacodynamics of cefazolin using total and unbound serum concentrations in patients with high body weight.
Chung EK; Cheatham SC; Healy DP; Stock AH; Utley S; Campion M; Murrey T; Gesenhues AM; Jeffery J; Kays MB
Int J Antimicrob Agents; 2023 Apr; 61(4):106751. PubMed ID: 36758780
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.
Ikawa K; Morikawa N; Uehara S; Monden K; Yamada Y; Honda N; Kumon H
Int J Antimicrob Agents; 2009 Mar; 33(3):276-9. PubMed ID: 19095418
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics of Doripenem in Pediatric Patients and Monte-Carlo Pharmacokinetic-Pharmacodynamic Simulations for Dosing Regimen Assessment.
Matsuo Y; Ishibashi T; Matsumoto S; Katsube T; Wajima T
J Pharm Sci; 2019 Sep; 108(9):3099-3105. PubMed ID: 30974120
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
